These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 1980930

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus.
    Inoue Y, Kaku K, Kaneko T, Matsumura S, Nakayama H, Yoshizaki Y, Ando S, Inoue M, Hatao M.
    J Int Med Res; 1996; 24(1):138-46. PubMed ID: 8674792
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. Short-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
    Lijnen P, Fagard R, Staessen J, Amery A.
    J Cardiovasc Pharmacol; 1988 Oct; 12(4):461-6. PubMed ID: 2465447
    [Abstract] [Full Text] [Related]

  • 66. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL, Taylor AA, Nelson EB.
    Am J Med; 1989 Aug 16; 87(2A):57S-61S. PubMed ID: 2569825
    [Abstract] [Full Text] [Related]

  • 67. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
    Andersen P, Seljeflot I, Herzog A, Arnesen H, Hjermann I, Holme I.
    J Cardiovasc Pharmacol; 1998 May 16; 31(5):677-83. PubMed ID: 9593066
    [Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
    Diabet Med; 1994 Oct 16; 11(8):773-82. PubMed ID: 7851072
    [Abstract] [Full Text] [Related]

  • 70. Metabolic effects of a change in antihypertensive treatment.
    Lithell H, Aberg H, Selinus I.
    Am J Med; 1986 Feb 14; 80(2A):114-9. PubMed ID: 3511690
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Alpha 1 blockers: antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored.
    Waite MA.
    J Intern Med Suppl; 1991 Feb 14; 735():113-7. PubMed ID: 1675053
    [Abstract] [Full Text] [Related]

  • 75. The pharmacokinetics and pharmacodynamics of doxazosin compared with atenolol during long-term double-blind treatment.
    Faulkner JK, Himanen P, Karjalainen U, Saraste M.
    Eur J Clin Pharmacol; 1987 Feb 14; 31(6):685-93. PubMed ID: 2951261
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
    Courtney CH, McCance DR, Atkinson AB, Bassett J, Ennis CN, Sheridan B, Bell PM.
    Metabolism; 2003 Sep 14; 52(9):1147-52. PubMed ID: 14506621
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.